NASDAQ:NOVN Novan (NOVN) Stock Price, News & Analysis → Claim Your Complimentary Bitcoin Reward (From Crypto Swap Profits) (Ad) Free NOVN Stock Alerts $0.0008 0.00 (0.00%) (As of 03/15/2024 ET) Add Compare Share Share Today's Range$0.0008▼$0.000850-Day Range N/A52-Week Range$0.08▼$3.33Volume361 shsAverage Volume602,421 shsMarket Capitalization$22,412.00P/E RatioN/ADividend YieldN/APrice Target$8.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsSocial Media Get Novan alerts: Email Address Novan MarketRank™ Stock AnalysisAnalyst RatingHold2.33 Rating ScoreUpside/Downside999,900.0% Upside$8.00 Price TargetShort InterestN/ADividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.72) to ($0.33) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.98 out of 5 stars 3.2 Analyst's Opinion Consensus RatingNovan has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 1 buy rating, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $8.00, Novan has a forecasted upside of 999,900.0% from its current price of $0.00.Amount of Analyst CoverageNovan has received no research coverage in the past 90 days. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for NOVN. Previous Next 0.0 Dividend Strength Dividend YieldNovan does not currently pay a dividend.Dividend GrowthNovan does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for NOVN. Previous Next 1.1 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 1 news article for Novan this week, compared to 0 articles on an average week.Search Interest1 people have searched for NOVN on MarketBeat in the last 30 days. MarketBeat Follows3 people have added Novan to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Novan insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.30% of the stock of Novan is held by insiders.Percentage Held by InstitutionsOnly 14.51% of the stock of Novan is held by institutions. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Novan are expected to grow in the coming year, from ($0.72) to ($0.33) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Novan is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Novan is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNovan has a P/B Ratio of 0.00. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsBlackRock Bets Big on Tiny BiotechAn undervalued biotech firm is on the verge of a major discovery - That has the potential to treat Alzheimer's, Parkinson's and Dementia. BlackRock is so confident in this firm, they've invested $298 million. Click here for the full story >>> About Novan Stock (NASDAQ:NOVN)Novan, Inc., a medical dermatology company, focuses on developing and commercializing therapeutic products for skin diseases. Its clinical stage dermatology drug candidates include SB204, a topical monotherapy for the treatment of acne vulgaris; SB206, a topical anti-viral gel for the treatment of viral skin infections; SB208, a topical broad-spectrum anti-fungal gel for the treatment of fungal infections of the skin and nails, including athlete's foot and fungal nail infections; and SB414, a topical cream-based gel product candidate for the treatment of inflammatory skin diseases. The company develops SB207, an anti-viral product candidate for the treatment of external genital warts; WH602, a nitric oxide-containing intravaginal gel to treat high-risk human papilloma virus (HPV); WH504, a non-gel formulation product candidate to treat high-risk HPV; and SB019 for the treatment of SARS-CoV-2. Novan, Inc. has a license agreement with Sato Pharmaceutical Co., Ltd.; and a strategic alliance with Orion Corporation. The company was incorporated in 2006 and is headquartered in Durham, North Carolina.Read More NOVN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NOVN Stock News HeadlinesMarch 14, 2024 | americanbankingnews.comNovan (NASDAQ:NOVN) Now Covered by Analysts at StockNews.comFebruary 27, 2024 | wsj.comNovartis AGMarch 18, 2024 | InvestorPlace (Ad)They said crypto was dead. It went up 100X.Bitcoin’s haters are out again. Despite the price doubling in the last six months alone… That hasn’t stopped the experts from piling on. Warren Buffett’s right-hand man Charlie Munger called crypto investors “idiots” in one of his last interviews. JPMorgan CEO Jamie Dimon, recently called Bitcoin a “pet rock” and “a hyped-up fraud.” But when it comes to cryptos, these are exactly the people you shouldn’t listen to. They’ve predicted crypto’s demise for years.February 16, 2024 | morningstar.comNovartis AG Registered SharesOctober 31, 2023 | morningstar.comNovartis AG Registered Shares NOVNSeptember 8, 2023 | bizjournals.comNovan reaches deals to sell assets in bankruptcy caseAugust 8, 2023 | msn.comFirm Retention Summary: NovanAugust 3, 2023 | msn.comNovan (NOVN) Price Target Increased by 43.52% to 15.81March 18, 2024 | Crypto 101 Media (Ad)Like Tiny Crypto Retirement FundsThe crypto bull market is about to blast off. Bitcoin and Ethereum are surging. But so are tiny altcoins that could be so profitable… They're like tiny crypto retirement funds. July 17, 2023 | marketwatch.comNovan Shares Hit 52-Week Low After Bankruptcy DeclarationJune 1, 2023 | bizjournals.comNovan cuts 50% of its workforce to extend runwayJune 1, 2023 | msn.comNovan drops 13%, will reduce workforce by 50%May 31, 2023 | markets.businessinsider.comNovan To "Sharpen" Focus, Resources On Berdazimer GelMay 31, 2023 | finance.yahoo.comNovan Focuses Strategic Direction and Announces RestructuringMay 21, 2023 | fool.comNovan (NASDAQ: NOVN)May 17, 2023 | msn.comOppenheimer Maintains Novan (NOVN) Outperform RecommendationMay 16, 2023 | finance.yahoo.comNOVN: Counting Down to PDUFAMay 15, 2023 | finanznachrichten.deNovan, Inc.: Novan Reports First Quarter 2023 Financial Results and Provides Corporate UpdateMay 15, 2023 | markets.businessinsider.comNovan earnings: here's what Wall Street expectsMay 12, 2023 | msn.comEarnings Preview: NovanMay 12, 2023 | msn.comNovan Q1 2023 Earnings PreviewApril 20, 2023 | finance.yahoo.comNovan to Host Analyst and Investor Event: A Discussion of Molluscum’s Unmet Need with Pediatric Dermatologist Jeffrey Sugarman, MD, PhDApril 3, 2023 | msn.comNovan's Return On Capital Employed OverviewMarch 23, 2023 | finance.yahoo.comNovan to Report Full Year 2022 Financial Results on March 30, 2023March 7, 2023 | finance.yahoo.comFDA Accepts Novan’s NDA for Berdazimer Gel, 10.3% for the Treatment of Molluscum Contagiosum with a PDUFA Goal Date of January 5, 2024October 19, 2022 | reuters.comJPMorgan names Qian as Southeast Asia equity capital markets chief - ReutersOctober 14, 2022 | finance.yahoo.comNovan and EPI Health, a Novan Company, Announce Abstracts Accepted for Poster Presentation at the 42nd Annual Fall Clinical Dermatology Conference® - Yahoo FinanceSee More Headlines Receive NOVN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Novan and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/15/2023Today3/18/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:NOVN CUSIPN/A CIK1467154 Webwww.novan.com Phone(919) 485-8080Fax919-237-9212Employees90Year FoundedN/APrice Target and Rating Average Stock Price Target$8.00 High Stock Price Target$8.00 Low Stock Price Target$8.00 Potential Upside/Downside+999,900.0%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($1.32) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-31,310,000.00 Net Margins-128.61% Pretax Margin-128.39% Return on Equity-700.28% Return on Assets-39.58% Debt Debt-to-Equity RatioN/A Current Ratio0.74 Quick Ratio0.72 Sales & Book Value Annual Sales$24.71 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value$0.19 per share Price / Book0.00Miscellaneous Outstanding Shares28,015,000Free Float27,651,000Market Cap$22,412.00 OptionableNot Optionable Beta-0.06 The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report Key ExecutivesMs. Paula Brown Stafford M.P.H. (Age 58)Pres, CEO & Chairwoman Comp: $623.23kMr. John M. Gay CPA (Age 46)CFO, Principal Accounting Officer & Corp. Sec. Comp: $386.89kMr. John A. Donofrio Jr. (Age 56)Exec. VP & COO Comp: $602.51kDr. Carri Geer Ph.D.Sr. VP & CTODr. Tomoko Maeda-Chubachi M.B.A.M.D., Ph.D., Chief Medical OfficerKey CompetitorsCNS PharmaceuticalsNASDAQ:CNSPChina PharmaNYSE:CPHISalarius PharmaceuticalsNASDAQ:SLRXClearmind MedicineNASDAQ:CMNDProcessa PharmaceuticalsNASDAQ:PCSAView All CompetitorsInsidersMachelle SandersSold 11,553 sharesTotal: $4,736.73 ($0.41/share)View All Insider Transactions NOVN Stock Analysis - Frequently Asked Questions Should I buy or sell Novan stock right now? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novan in the last year. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" NOVN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NOVN, but not buy additional shares or sell existing shares. View NOVN analyst ratings or view top-rated stocks. What is Novan's stock price target for 2024? 3 Wall Street research analysts have issued 1 year price objectives for Novan's shares. Their NOVN share price targets range from $8.00 to $8.00. On average, they predict the company's share price to reach $8.00 in the next year. This suggests a possible upside of 999,900.0% from the stock's current price. View analysts price targets for NOVN or view top-rated stocks among Wall Street analysts. How have NOVN shares performed in 2024? Novan's stock was trading at $0.0005 on January 1st, 2024. Since then, NOVN shares have increased by 60.0% and is now trading at $0.0008. View the best growth stocks for 2024 here. How were Novan's earnings last quarter? Novan, Inc. (NASDAQ:NOVN) released its quarterly earnings data on Monday, May, 15th. The company reported ($0.54) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.32) by $0.22. The firm had revenue of $3.17 million for the quarter, compared to analyst estimates of $6.19 million. Novan had a negative trailing twelve-month return on equity of 700.28% and a negative net margin of 128.61%. During the same quarter in the previous year, the company earned ($0.71) EPS. What other stocks do shareholders of Novan own? Based on aggregate information from My MarketBeat watchlists, some companies that other Novan investors own include Bionano Genomics (BNGO), Gran Tierra Energy (GTE), Pennsylvania Real Estate Investment Trust (PEI), ADMA Biologics (ADMA), CNBX Pharmaceuticals (CNBX), Matinas BioPharma (MTNB), Zosano Pharma (ZSAN), Aeterna Zentaris (AEZS), CBL & Associates Properties (CBL) and Organigram (OGI). When did Novan IPO? (NOVN) raised $46 million in an initial public offering on Wednesday, September 21st 2016. The company issued 3,800,000 shares at $11.00-$13.00 per share. Piper Jaffray served as the underwriter for the IPO and JMP Securities and Wedbush PacGrow were co-managers. How do I buy shares of Novan? Shares of NOVN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:NOVN) was last updated on 3/18/2024 by MarketBeat.com Staff From Our PartnersCentral Bank Gold Heist In ProgressColonial MetalsLike Tiny Crypto Retirement FundsCrypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceDid you make $29,000 two days with AI options trades?Prosper Trading AcademyThe world’s greatest investmentPorter & CompanyForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill Publishingtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyStock-Picking AI Predicts #1 Stock of 2024Altimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Novan, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.